Cantor Fitzgerald Reaffirms Overweight Rating for Lexeo Therapeutics (NASDAQ:LXEO)

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports.

Several other equities research analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Leerink Partners reiterated an “outperform” rating and set a $15.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, September 23rd. Wall Street Zen raised Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 19th. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Lexeo Therapeutics in a research note on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and a consensus target price of $16.43.

Lexeo Therapeutics Stock Performance

NASDAQ LXEO opened at $3.07 on Thursday. The firm has a 50-day moving average of $3.46 and a 200-day moving average of $5.05. The stock has a market cap of $251.89 million, a PE ratio of -2.67 and a beta of 1.64. Lexeo Therapeutics has a 52-week low of $2.55 and a 52-week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). As a group, analysts predict that Lexeo Therapeutics will post -1.22 EPS for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Montanova Capital LLC boosted its holdings in Lexeo Therapeutics by 410.7% in the 2nd quarter. Montanova Capital LLC now owns 6,384,200 shares of the company’s stock valued at $29,718,000 after purchasing an additional 5,134,200 shares during the period. Affinity Asset Advisors LLC increased its holdings in shares of Lexeo Therapeutics by 57.8% during the first quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after purchasing an additional 1,850,211 shares during the period. BlackRock Inc. bought a new position in shares of Lexeo Therapeutics during the second quarter worth approximately $26,717,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Lexeo Therapeutics by 9.0% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,824,725 shares of the company’s stock worth $22,459,000 after purchasing an additional 400,000 shares during the period. Finally, Orbimed Advisors LLC raised its position in shares of Lexeo Therapeutics by 69.5% in the first quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock valued at $20,678,000 after buying an additional 1,477,450 shares in the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.